Search Results - "Ko, Eric C."

Radiotherapy and checkpoint inhibitors: a winning new combination? by Ko, Eric C., Formenti, Silvia C.

“…Immune checkpoint blockade has recently emerged as an important therapeutic approach to the management of malignancies across multiple disease settings…”
Get full text

Radiation unlocks the therapeutic potential of immune checkpoint blockers in lung cancer patients by Ko, Eric C., Galluzzi, Lorenzo

“…CTLA4 blockers have limited activity in patients with chemorefractory lung cancer. Recent clinical data demonstrate that radiation therapy combined with CTLA4…”
Get full text

Generating antitumor immunity by targeted radiation therapy: Role of dose and fractionation by Ko, Eric C., MD, PhD, Benjamin, Kimberly Thomas, MD, Formenti, Silvia C., MD

“…Abstract Accumulating evidence supports the role of radiation therapy in the induction of antitumor immunity. With recent advancements in stereotactic…”
Get full text

Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases by Tong, Charles C L, Ko, Eric C, Sung, Max W, Cesaretti, Jamie A, Stock, Richard G, Packer, Stuart H, Forsythe, Kevin, Genden, Eric M, Schwartz, Myron, Lau, K H Vincent, Galsky, Matthew, Ozao-Choy, Junko, Chen, Shu-Hsia, Kao, Johnny

“…Preclinical data suggest that sunitinib enhances the efficacy of radiotherapy. We tested the combination of sunitinib and hypofractionated image-guided…”
Get full text

Epidemiology of head and neck squamous cell cancer among HIV-infected patients by Dʼsouza, Gypsyamber, Carey, Thomas E, William, Jr, William N, Nguyen, Minh Ly, Ko, Eric C, Riddell, 4th, James, Pai, Sara I, Gupta, Vishal, Walline, Heather M, Lee, J Jack, Wolf, Gregory T, Shin, Dong M, Grandis, Jennifer R, Ferris, Robert L

“…HIV-infected individuals have a higher incidence of head and neck cancer (HNC). Case series of 94 HIV-infected HNC patients (HIV-HNC) at 6 tertiary care…”
Get full text

The Integration of Radiotherapy with Immunotherapy for the Treatment of Non-Small Cell Lung Cancer by Ko, Eric C, Raben, David, Formenti, Silvia C

“…Five-year survival rates for non-small cell lung cancer (NSCLC) range from 14% to 49% for stage I to stage IIIA disease, and are <5% for stage IIIB/IV disease…”
Get full text

Postoperative Radiation after Radical Prostatectomy by Ko, Eric C., M.D., Ph.D, Michaud, Anthony L., M.D., Ph.D, Valicenti, Richard K., M.D., M.A., F.A.S.T.R.O

“…Three randomized clinical trials have demonstrated a significant clinical benefit with adjuvant radiation in high-risk prostate cancer patients after radical…”
Get full text

Radiation therapy to enhance tumor immunotherapy: a novel application for an established modality by Ko, Eric C., Formenti, Silvia C.

“…Purpose: The aim of this review is to highlight key evidence supporting the effect of radiation therapy on tumor immunity. Conclusions: Recent findings in both…”
Get full text

γ-H2AX kinetics as a novel approach to high content screening for small molecule radiosensitizers by Fu, Shibo, Yang, Ying, Das, Tirtha K, Tirtha, Das, Yen, Yun, Zhou, Bing-sen, Zhou, Ming-Ming, Ohlmeyer, Michael, Ko, Eric C, Cagan, Ross, Rosenstein, Barry S, Chen, Shu-hsia, Kao, Johnny

“…Persistence of γ-H2AX after ionizing radiation (IR) or drug therapy is a robust reporter of unrepaired DNA double strand breaks in treated cells. DU-145…”
Get full text

PSA Nadir of <0.5 ng/mL Following Brachytherapy for Early-Stage Prostate Adenocarcinoma is Associated With Freedom From Prostate-Specific Antigen Failure by Ko, Eric C., M.D., Ph.D, Stone, Nelson N., M.D, Stock, Richard G., M.D

“…Purpose Because limited information exists regarding whether the rate or magnitude of PSA decline following brachytherapy predicts long-term clinical outcomes,…”
Get full text

Radiotherapy and Immunotherapy Combinations for Lung Cancer by Agrawal, Vishesh, Benjamin, Kimberly Thomas, Ko, Eric C.

“…Purpose of Review Positive results from recent immunotherapy trials of non-small cell lung cancer (NSCLC) have coincided with a greater appreciation for the…”
Get full text

Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy by Chen, Hui-Ming, Ma, Ge, Gildener-Leapman, Neil, Eisenstein, Samuel, Coakley, Brian A, Ozao, Junko, Mandeli, John, Divino, Celia, Schwartz, Myron, Sung, Max, Ferris, Robert, Kao, Johnny, Wang, Lu-Hai, Pan, Ping-Ying, Ko, Eric C, Chen, Shu-Hsia

“…The clinical effects of sunitinib on human myeloid-derived suppressor cell (MDSC) subsets and correlation of the T-cell-mediated immune responses and clinical…”
Get full text

Stereotactic body radiation therapy for metastatic non-small cell lung cancer: a versatile treatment, repurposed by Shen, James L, Ko, Eric C

Get full text

Narrative review of stereotactic body radiation therapy combined with tyrosine kinase inhibitors for oligometastatic EGFR-mutated non-small cell lung cancer: present and future developments by Zhao, Xinchen, Zhang, Shengwei, Sun, Xiaoyue, Lin, Yao, Capone, Luca, Ko, Eric C., Kann, Benjamin H., Li, Yi, Wang, Xiaoshan

Get full text

Treatment strategies in low-volume metastatic castration-resistant prostate cancer by Wei, Xiao X, Ko, Eric C, Ryan, Charles J

“…PURPOSE OF REVIEWThere are currently limited data to guide the optimal management of patients with low-volume metastatic castration-resistant prostate cancer…”
Get full text

Definitive Radiation Therapy for Medically Inoperable Endometrial Carcinoma by Shen, James L., O'Connor, Kevin W., Moni, Janaki, Zweizig, Susan, Fitzgerald, Thomas J., Ko, Eric C.

“…Upfront radiation therapy consisting of brachytherapy with or without external beam radiation therapy is considered standard of care for patients with…”
Get full text

First Report of NRG Oncology/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinically Nonmetastatic Prostate Cancer After Radical Prostatectomy by Valicenti, Richard K., Pugh, Stephanie L., Trabulsi, Edouard J., Sartor, Oliver, Ko, Eric C., Girvigian, Michael R., Rosenthal, Seth A., Shaves, Mark E., Hoffman-Censits, Jeannie H., Schallenkamp, John, Sandler, Howard M.

“…To investigate the utility of 153Sm lexidronam (Quadramet) in the setting of men with prostate cancer status post radical prostatectomy who develop biochemical…”
Get full text

Association of early PSA failure time with increased distant metastasis and decreased survival in prostate brachytherapy patients by Ko, Eric C, Liu, Jerry T, Stone, Nelson N, Stock, Richard G

“…Abstract Background and purpose We investigated whether earlier PSA failure following prostate brachytherapy is associated with increased rates of distant…”
Get full text

Targeting immune suppressing myeloid-derived suppressor cells in oncology by Kao, Johnny, Ko, Eric C, Eisenstein, Samuel, Sikora, Andrew G, Fu, Shibo, Chen, Shu-hsia

“…Abstract Emerging data suggests that host immune cells with a suppressive phenotype represent a significant hurdle to successful therapy for metastatic cancer…”
Get full text

Tolerability, Toxicity, and Temporal Implications of Transoral Robotic Surgery (TORS) on Adjuvant Radiation Therapy in Carcinoma of the Head and Neck by Carpenter, Todd J., Kann, Benjamin, Buckstein, Michael H., Ko, Eric C., Bakst, Richard L., Misiukiewicz, Krzysztof J., Posner, Marshall R., Genden, Eric M., Gupta, Vishal

“…Objectives: Overall treatment package time (from surgery to radiotherapy [RT] completion) > 100 days can portend poor outcomes in head and neck cancer. Faster…”
Get full text